[Form 4] Orchestra BioMed Holdings, Inc. Insider Trading Activity

Rhea-AI Filing Summary

David P. Hochman, Chief Executive Officer and Chairperson of Orchestra BioMed Holdings, Inc. (OBIO), reported purchasing a total of 6,000 shares of the company's common stock on 08/21/2025 at a weighted-average price of $2.49 per share (individual trade prices ranged from $2.49 to $2.50). After the reported purchase, Mr. Hochman beneficially owns 651,460 shares directly and additional shares indirectly via multiple family trusts (total indirect positions listed: 449,331; 2,000; 2,000; 2,000; 3,140). The Form 4 was signed by an attorney-in-fact on 08/25/2025. The filing discloses insider buying by the CEO/chair but does not provide reasons for the transactions.

Positive

• Insider purchase reported: CEO/chair acquired 6,000 shares on 08/21/2025 at a weighted-average price of $2.49.
• Substantial insider ownership remains: Reporting person holds 651,460 shares directly and meaningful indirect trust holdings, indicating alignment with shareholders.

Negative

• None.

Insights

Corporate Governance Expert

TL;DR: CEO and chair purchased a small number of shares, modestly increasing his direct stake, which signals insider confidence but is not a material shift.

The acquisition of 6,000 shares by the CEO/chair at about $2.49 per share is a standard insider purchase disclosed on Form 4. The filing shows substantial existing ownership (over 651k shares directly plus meaningful indirect trust holdings), indicating long-standing insider alignment with shareholders. The transaction size is modest relative to total holdings, so while it is a supportive signal, it is unlikely to materially affect control or valuation.

Securities Analyst

TL;DR: Insider buying is a positive behavioral signal but small relative to reported ownership; limited direct market impact.

The reported weighted-average purchase price range ($2.49–$2.50) and the 6,000-share size are fully disclosed and routine. The incremental purchase increases direct beneficial ownership to 651,460 shares but represents a small percentage change versus that base. No derivative transactions or sales are reported. From a market-impact perspective, this disclosure is informational but not material in isolation.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Hochman David P

(Last) (First) (Middle)

C/O ORCHESTRA BIOMED HOLDINGS, INC.

150 UNION SQUARE DRIVE

(Street)

NEW HOPE PA 18938

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Orchestra BioMed Holdings, Inc. [ OBIO ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	See Remarks

3. Date of Earliest Transaction (Month/Day/Year)
08/21/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock, par value $0.0001 per share ("Common Stock")	08/21/2025		P		6,000	A	$2.49(1)	651,460	D
Common Stock								449,331	I	By the DPH 2008 Trust
Common Stock								2,000	I	By the Solomon Ascher Hochman 2019 Trust
Common Stock								2,000	I	By the Hannah Hochman 2019 Trust
Common Stock								2,000	I	By the Judah Herman Hochman 2019 Trust
Common Stock								3,140	I	By the NSH 2008 Family Trust

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $2.49 to $2.50. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.

Remarks:

Chief Executive Officer and Chairperson

	/s/ Andrew Taylor, Attorney-in-Fact	08/25/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did OBIO insider David P. Hochman report on Form 4?

The Form 4 reports that David P. Hochman purchased 6,000 shares of Orchestra BioMed (OBIO) on 08/21/2025 at a weighted-average price of $2.49 per share.

How many OBIO shares does the reporting person own after the transaction?

After the reported purchase, the reporting person directly beneficially owns 651,460 shares and also holds indirect positions via family trusts totaling the amounts disclosed in the filing.

Was the Form 4 signed and when?

Yes. The Form 4 was signed by an attorney-in-fact (/s/ Andrew Taylor) on 08/25/2025 as reflected in the filing.

Did the filing disclose any derivative transactions or sales?

No. The filing shows only a non-derivative purchase of common stock; Table II (derivative securities) contains no reported transactions.

What price range were the shares purchased at?

The footnote states the shares were purchased at prices ranging from $2.49 to $2.50, with the reported price being a weighted average of $2.49.